Loading…
Loading…
WXIBF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for WXIBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WXIBF and 80,000+ other tickers.
See exactly how WXIBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WXIBF and 80,000+ other tickers.
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives. Furthermore, it provides clinical and manufacturing support for biologics, manufactures and distributes medical products…
